| human lymphocyte antigen | A system designation for the gene products of at least four linked loci (A, B, C, and D) and a member of subloci on the sixth human chromosome which have been shown to have a strong influence on human allotransplantation, transfusions in refractory patients, and certain disease associations; more than 50 alleles are recognised, most of which are at loci HLA-A and HLA-B; autosomal dominant inheritance. (05 Mar 2000) |
|---|---|
| human measles immune serum | Obtained from the blood of a healthy person who has survived an attack of measles. Synonym: measles convalescent serum. (05 Mar 2000) |
| human menopausal gonadotropin | A hormone of pituitary originally obtained from the urine of postmenopausal women now produced synthetically; used to induce ovulation. See: menotropins. (05 Mar 2000) |
| human normal immunoglobulin | A preparation of the proteins of liquid human plasma, containing the antibodies of normal adults; it is obtained from pooled liquid human plasma from a number of donors and may be prepared by precipitation with organic solvents under controlled conditions of pH, ionic strength, and temperature. Synonym: human normal immunoglobulin. (05 Mar 2000) |
| human papilloma virus | <virology> A disease caused by the human papilloma virus characterised by a soft wart-like growth on the genitalia (for example penis, vulva). In adults this infection is most commonly transmitted sexually. Genital warts are very common and are increasing in incidence. Safe sex practices, such as using condoms can help decrease the risk of infection. Treatment includes several topical agents to eradicate the lesions, cryosurgery, laser therapy, electrocauterisation or surgical removal. See: alternate name condyloma acuminata. Acronym: HPV (27 Sep 1997) |
| human pertussis immune serum | The sterile serum prepared from the pooled blood of healthy adult human beings who have received repeated courses of phase I pertussis vaccine; administered intravenously or intramuscularly for the prophylaxis or treatment of whooping cough. (05 Mar 2000) |
| human plasma protein fraction | A sterile solution of selected proteins derived from the blood plasma of adult human donors, containing 4.5 to 5.5 g of protein per 100 ml, of which 83 to 90% is albumin and the remainder is alpha-and beta-globulins; used as a blood volume supporter. (05 Mar 2000) |
| human rights | The rights of the individual to cultural, social, economic, and educational opportunities as provided by society, e.g., right to work, right to education, and right to social security. (12 Dec 1998) |
| human scarlet fever immune serum | Scarlet fever convalescent serum, obtained from healthy persons who have survived an attack of scarlet fever. (05 Mar 2000) |
| human serum | See: dried human serum, normal human serum. (05 Mar 2000) |
| human serum jaundice | An obsolete name for hepatitis transmitted parenterally, usually by blood or blood products; usually due to hepatitis B. (05 Mar 2000) |
| human T-cell leukaemia virus | <virology> One of a group of retroviruses which causes the disease T-cell leukaemia in humans. T-cell leukaemia is a type of the cancer leukaemia where the body uncontrollably produces large amounts of abnormal (nonworking) T lymphocytes. (09 Oct 1997) |
| human T-cell lymphoma/leukaemia virus | A group of viruses (subfamily Oncovirinae, family Retroviridae) that are lymphotropic with a selective affinity for the helper/inducer cell subset of T lymphocytes and that are associated with adult T-cell leukaemia and lymphoma. Synonym: human T-cell lymphotropic virus. (05 Mar 2000) |
| human T-cell lymphotropic virus | A group of viruses (subfamily Oncovirinae, family Retroviridae) that are lymphotropic with a selective affinity for the helper/inducer cell subset of T lymphocytes and that are associated with adult T-cell leukaemia and lymphoma. Synonym: human T-cell lymphotropic virus. (05 Mar 2000) |
| human thioesterase | <enzyme> Homologous to e. Coli thioesterase II; not similar to animal thioesterases I or II; genbank x86032 Registry number: EC 3.1.2.- (26 Jun 1999) |